Journal article
Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).
Abstract
682
Background: Cabozantinib is a multitargeted tyrosine kinase inhibitor (TKI) that has demonstrated efficacy in mRCC randomized trials. Less is known about the activity of cabozantinib in patients (pts) exposed to immuno-oncology (IO) agents. We explored the real-world effectiveness of cabozantinib, including in pts who had progressed on IO therapy. Methods: Using CKCis, a prospective Canadian database, pts treated with …
Authors
Zhang H; Basappa NS; Joy I; Ghosh S; Lalani A-KA; Hansen AR; Heng DYC; Castonguay V; Kollmannsberger CK; Winquist E
Journal
Journal of Clinical Oncology, Vol. 38, No. 6_suppl, pp. 682–682
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2020
DOI
10.1200/jco.2020.38.6_suppl.682
ISSN
0732-183X